Infant nutrition group Mead Johnson has lowered its full-year sales and earnings outlook despite noting progress has been made on lifting its sales trajectory in China.
Reporting its third-quarter results, Mead Johnson said it now anticipates full-year net sales of 6% to 7% below the prior year on a reported basis and 2% to 3% below the prior year on a constant dollar basis. The company also revised its forecast for annual earnings per share to $2.80 to $2.87 due to lower sales.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
“We are operating in a challenging global environment and it is now clear that our growth will occur more slowly than we had planned. In this environment, we have chosen to revise our full-year guidance for both top and bottom line numbers,” CEO Kasper Jakobsen said.
However, Jakobsen noted: “We continue to make progress against our global plan. Most critically, we have made substantial progress in China.”
The company, which has seen revenue in China hit by regulatory changes and a rapid channel shift, said it has gained momentum behind new products in the country, where sales have stabilised.
Total net sales were 4% lower than last year falling to US$937.5m. However, the decrease was due to currency exchange. Revenue was in-line with last year on a constant-dollar basis.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLower sales did impact the company’s EBIT. Operating profit fell to $228.2m versus $239.2m despite a slight improvement in operating margin, which increased to 24% of sales up from 23%.
Net earnings in the three months to 30 September totalled $148.6m compared to $154.6m.
